Metformin discontinuation strategies
Pro Research Analysisby 
Searched over 200M research papers
Metformin Discontinuation Strategies in Type 2 Diabetes: Key Considerations
Discontinuation in Advanced Chronic Kidney Disease (CKD)
Current guidelines often recommend stopping metformin when a patient’s estimated glomerular filtration rate (eGFR) drops below 30 ml/min/1.73m² due to concerns about lactic acidosis. However, recent large-scale studies suggest that discontinuing metformin in patients with advanced CKD may actually increase the risk of death, major adverse cardiovascular events (MACE), and progression to end-stage kidney disease (ESKD) compared to those who continue metformin, with no significant increase in lactic acidosis risk observed in real-world data 135. These findings indicate that continuing metformin below the traditional eGFR threshold may offer cardiovascular and renal benefits, but further research is needed to confirm these results and to balance these benefits against potential risks 135.
Patterns and Predictors of Metformin Discontinuation
Discontinuation of metformin is common, especially when patients start second-line glucose-lowering therapies or experience declining renal function. Factors associated with higher rates of discontinuation include older age and a history of CKD . Discontinuation rates also vary by region, ethnicity, and healthcare factors, with some populations more likely to stop and then restart metformin multiple times, highlighting the dynamic nature of metformin use 24. Over time, the likelihood of discontinuing metformin after reaching reduced renal function has decreased, but it remains more likely than discontinuation of some other diabetes medications .
Clinical Outcomes After Discontinuation
When metformin is stopped, patients often require uptitration of other diabetes medications, such as insulin or sulfonylureas, to maintain glycemic control. While glycemic control can be maintained, this switch is frequently associated with increased risk of hypoglycemia, weight gain, and higher medication costs compared to continued metformin use 78. Some studies found no significant change in HbA1c after discontinuation, but noted that improved glycemic control post-discontinuation could signal further renal decline, and a notable proportion of patients experienced hypoglycemia . Providers are encouraged to consider the expanded recommendations for metformin use in mild to moderate renal dysfunction to avoid these adverse effects .
Temporary Discontinuation for Diagnostic Procedures
For patients undergoing FDG PET/CT scans, discontinuing metformin for 24 to 48 hours can reduce bowel uptake of the tracer, improving scan quality. A 48-hour discontinuation is more effective than 24 hours, but may result in higher blood glucose levels on the day of the scan .
Adherence and Reinitiation
Non-adherence to metformin is common, with a significant proportion of patients discontinuing and then reinitiating therapy within a few years. Adherence is influenced by factors such as age, side effects (especially gastrointestinal), and polypharmacy. Non-adherence to metformin is also associated with non-adherence to other therapies, such as endocrine therapy in cancer patients 29.
Conclusion
Metformin discontinuation strategies should be individualized, especially in patients with advanced CKD, where emerging evidence suggests potential benefits to continued use. Discontinuation often leads to increased risk of adverse outcomes, including cardiovascular and renal events, as well as higher rates of hypoglycemia and weight gain with alternative therapies. Temporary discontinuation may be warranted for certain diagnostic procedures. Overall, careful consideration of patient-specific factors and ongoing research are essential to optimize metformin management in clinical practice.
Sources and full results
Most relevant research papers on this topic